$ARDX News
Last published 1d ago
- 1d agoARDXArdelyx to Participate at the Jefferies Global Healthcare Conference in LondonGlobeNewswireWALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / ...
- 1w agoARDXARDELYX Q3 2026 EARNINGS - ARDELYX INCEarnings Call Transcriptspay as little as zero dollars. Talk to your health. Welcome to the Ardelix third quarter 2026 earnings call. All participants will be in a listen-only mode. I would now like to turn the conference over to Lisa Caporelli,
- 1w agoARDXARDELYX Q3 2026 EARNINGS - ARDELYX INCEarnings Call TranscriptsWelcome to the Ardelix Third Quarter 2026 Earnings Call. All participants will be in a listen-only mode. I would now like to turn the conference over to Lisa Caporelli, SVP, Investor Relations, and Corporate Communicatio
- 1w agoARDXARDELYX, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 1w agoARDXArdelyx Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ3 2026 total product revenue of $125.5 million, reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with $285.3 million in cash, cash
- 1w agoARDXArdelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic ConstipationGlobeNewswireTrial fully enrolled ahead of schedule Topline data expected in the second half of 2027 WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a
- 2w agoARDXSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDXGlobeNewswireNEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Ardelyx, Inc. (NASDAQ:ARDX) that Eric Foster, the Company's Chief Commercial Officer, is named as an individual defendant in a securities
- 2w agoARDXArdelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersGlobeNewswireReal-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated Additional data highlighted the challenges of managing hyperphosphatemia and the morbidity
- 3w agoARDXArdelyx to Report Third Quarter 2026 Financial Results on November 3, 2026GlobeNewswireWALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization
- 1mo agoARDXArdelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-CGlobeNewswireWALTHAM, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet
- 1mo agoARDXSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDXPR NewswireSueWallSt notifies investors in Ardelyx, Inc. (NASDAQ: ARDX) that Eric Foster, the Company's Chief Commercial Officer, is named as an individual...
- 1mo agoARDXArdelyx at Morgan Stanley 24th Annual Global Healthcare Conference - ARDELYX INCEarnings Call TranscriptsGreat. Good morning, everyone. My name is Bob Klingenberger. I'm with Morgan Stanley. Before we start with the Ardelics team, which we're very excited to have here, I just want to direct everyone to our research disclosu
- 1mo agoARDXMorgan Stanley 24th Annual Global Healthcare Conference - ARDELYX INCEarnings Call TranscriptsGreat. Good morning, everyone. My name is Bob Klingenberger. I'm with Morgan Stanley. Before we start with the Ardelics team, which we're very excited to have here, I just want to direct everyone to our research disclosu
- 2mo agoARDXArdelyx to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization
- 3mo agoARDXArdelyx Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to
- 3mo agoARDXArdelyx to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireWALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX) ("Ardelyx" or the "Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization
- 5mo agoARDXArdelyx to Participate at the Jefferies Global Healthcare Conference 2026GlobeNewswireWALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative
- 6mo agoARDXArdelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical MeetingsGlobeNewswireWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant
- 6mo agoARDXArdelyx Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireQ1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million Strong financial
- 6mo agoARDXArdelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical MeetingsGlobeNewswireWALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet
- 6mo agoARDXArdelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026GlobeNewswireWALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet
- 6mo agoARDXBMYArdelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal OfficerGlobeNewswireWALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical
- 6mo agoARDXArdelyx to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswireWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX) ("Ardelyx" or the "Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative
- 7mo agoARDXRajani Dinavahi, MD, Appointed Chief Medical Officer of ArdelyxGlobeNewswireWALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical
- 8mo agoARDXArdelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-CGlobeNewswireWALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical
- 8mo agoARDXArdelyx to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical
- 8mo agoARDXArdelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting MillionsGlobeNewswireDAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (NASDAQ:ARDX), a biopharmaceutical company with a vision of creating a healthier
- 8mo agoARDXArdelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireIBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA
- 9mo agoARDXArdelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026GlobeNewswireWALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 9mo agoARDXArdelyx Receives New Patent for TenapanorGlobeNewswireWALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 9mo agoARDXFirst Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELAGlobeNewswireWALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 9mo agoVRTXFATEMNKDARDXBreaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsPR NewswireThe medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven by a surge in funding for...
- 9mo agoARDXAVAIFATEMNKD+1Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease MarketsGlobeNewswireVANCOUVER, British Columbia, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The medical world is shifting as the global market for next-gen treatments heads toward $88.85 billion by 2030[1], driven
- 10mo agoARDXArdelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic OutlookGlobeNewswireCompany achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected
- 1y agoARDXReal-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney WeekGlobeNewswireWALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx to Participate at the Jefferies Global Healthcare Conference in LondonGlobeNewswireWALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor ConferenceGlobeNewswireWALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireQ3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between
- 1y agoARDXArdelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual MeetingGlobeNewswireIBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C
- 1y agoARDXArdelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney WeekGlobeNewswireWALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx to Report Third Quarter 2025 Financial Results on October 30, 2025GlobeNewswireWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial OfficerGlobeNewswireWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoARDXArdelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference TranscriptEarnings Call Transcripts
- 1y agoARDXArdelyx to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXArdelyx, Inc. (ARDX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoARDXArdelyx Announces Changes to the Executive Leadership TeamGlobeNewswireEdward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM,
- 1y agoARDXArdelyx Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireCompany reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated
- 1y agoARDXArdelyx to Report Second Quarter 2025 Financial Results on August 4, 2025GlobeNewswireWALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
- 1y agoARDXApproval of Xphozah, Nda #213931 (Labeling)FDA Approved DrugsApproval Date: 06/16/2025; Drug Name: Xphozah, Nda #213931; Active Ingredients: TENAPANOR HYDROCHLORIDE; Company: Ardelyx Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213931